Skip to main content

Tema Cardiovascular and Metabolic ETF (NYSE: HRTS) — Company Overview, News & Financial Data

Tema Cardiovascular and Metabolic ETF logo
HRTS Tema Cardiovascular and Metabolic ETF
Tema Cardiovascular and Metabolic ETF primary media
Company profile

Tema Cardiovascular and Metabolic ETF

About

Explore United States companies

Tema Obesity & Cardiometabolic ETF (NASDAQ:HRTS) is an exchange-traded fund (ETF) that invests in companies focused on developing solutions for obesity and cardiometabolic diseases. Launched in November 2023, HRTS tracks firms involved in weight-loss drugs, diabetes treatments, and other related areas. The fund offers exposure to this growing market with a relatively low expense ratio of 0.75%. It started trading around $26 per share and currently sits at $32, with over $61 million in assets under management.

Snapshot

Public USOwnership
2023Year founded
18Employees
New York, United StatesHead office
Loading Map...
Global footprint

Operations

All Locations
New York City, US

Products and/or services of Tema Cardiovascular and Metabolic ETF

  • Investing in companies pioneering cardiovascular treatments.
  • Funding metabolic disorder research initiatives.
  • Supporting technologies for non-invasive cardiovascular diagnostics.
  • Promoting advanced therapies for heart failure management.
  • Backing innovations in lipid management solutions.
  • Endorsing new approaches to obesity treatment development.